Skip to main content
Qyuns Therapeutics Co., Ltd. logo

Qyuns Therapeutics Co., Ltd. — Investor Relations & Filings

Ticker · 2509 ISIN · CNE1000069W9 HKEX Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2026-05-08 AGM Information
Country HK Hong Kong
Listing HKEX 2509

About Qyuns Therapeutics Co., Ltd.

http://www.qyuns.net

Qyuns Therapeutics Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research, development, industrialization, and commercialization of antibody drugs for autoimmune and allergic diseases. The company operates an integrated platform covering the entire value chain, from proprietary antibody discovery (including a rabbit antibody development platform) to cGMP-compliant, commercial-scale internal manufacturing. Qyuns focuses on improving drug accessibility and affordability in its target areas. Its robust pipeline features 10 drug candidates targeting major inflammatory pathways, such as IL-12/IL-23p40, IL-4R , IL-17A, IL-23p19, and TSLP. The pipeline addresses four key therapeutic areas: dermatology, rheumatology, respiratory, and digestive diseases, with several assets in late-stage clinical development.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 29, 2026
AGM Information Classification · 100% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of Qyuns Therapeutics Co., Ltd. It includes instructions for shareholders to appoint proxies to vote on various resolutions at the AGM, including approval of the annual report, board reports, auditor appointment, profit distribution, remuneration scheme, and share issuance mandates. The document is dated for a future AGM in 2026 and references the annual report and other materials to be reviewed at the meeting. It does not contain the actual annual report or financial statements but is a proxy voting form related to the AGM. Therefore, this document is classified as AGM Information (AGM-R).
2026-05-08 English
CIRCULAR FOR ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a circular for the 2025 Annual General Meeting (AGM) of Qyuns Therapeutics Co., Ltd. It includes multiple agenda items such as the 2025 work reports of the board and board of supervisors, the 2025 annual report, profit distribution plan, remuneration scheme for directors and supervisors, engagement of auditor, proposed changes in use of proceeds, share issuance and repurchase mandates, dissolution of the supervisory committee, and amendments to articles of association and procedural rules. It also contains the notice of the 2025 AGM and a proxy form. The document is comprehensive and intended to inform shareholders about the AGM agenda and related proposals, which is typical of AGM Information filings. It is not the annual report itself but a circular containing AGM materials and notice. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a full AGM circular.
2026-05-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 100% confidence The document is a monthly return filing to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Qyuns Therapeutics Co., Ltd. It details movements in authorized share capital, issued shares, treasury shares, and public float sufficiency confirmation for the month ended 30 April 2026. The document includes confirmations pursuant to HKEX listing rules about compliance and authorization of securities issued or treasury shares sold. It is a regulatory compliance report related to share capital and public float, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication but a regulatory filing itself. Therefore, the document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and compliance document that does not fit other specific categories.
2026-05-07 English
DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS
Regulatory Filings Classification · 65% confidence The document is an official announcement under the Hong Kong Listing Rules regarding Qyuns Therapeutics’ discloseable transactions involving subscriptions to wealth management products. It details transaction terms, board approvals, and Listing Rules implications but does not provide financial statements or serve as an earnings report. It is not a share issue, dividend notice, or capital raise; rather, it is a regulatory announcement of specific transactions. This falls under the catch-all “Regulatory Filings” category for miscellaneous compliance disclosures that do not fit other specific filing types.
2026-04-29 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 100% confidence The document is titled '2025 Environmental, Social and Governance (ESG) Report' for Qyuns Therapeutics Co., Ltd. It contains detailed sections on ESG governance, environmental compliance, social responsibility, corporate governance, and sustainability initiatives. The report covers the full year 2025 and includes key performance indicators, governance structure, and corporate social responsibility activities. It references the ESG Reporting Code issued by HKEX and is approved by the Board of Directors. The content is comprehensive and focused on environmental, social, and governance factors rather than financial results or management changes. Therefore, it fits the definition of an Environmental & Social Information report (ESG report).
2026-04-27 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2025 年度報告 ANNUAL REPORT' and contains detailed sections typical of an annual report, including Chairman's Statement, Financial Highlights, Management Discussion and Analysis, Biographies of Directors, Board Reports, Corporate Governance Report, Independent Auditor's Report, and full consolidated financial statements with notes. The content covers the full fiscal year ended December 31, 2025, with comprehensive financial data and analysis. The length is substantial (15,000 characters), indicating it is the full report, not just an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-27 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.